# A Study of Lebrikizumab in Combination With Topical Corticosteroids in Patients With Atopic Dermatitis (AD) That Are Not Adequately Controlled With or Are Non-eligible for Cyclosporine

> **NCT05149313** · PHASE3 · COMPLETED · sponsor: **Almirall, S.A.** · enrollment: 331 (actual)

## Conditions studied

- Dermatitis, Atopic
- Eczema

## Interventions

- **BIOLOGICAL:** Lebrikizumab
- **DRUG:** Lebrikizumab-matching Placebo

## Key facts

- **NCT ID:** NCT05149313
- **Lead sponsor:** Almirall, S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-23
- **Primary completion:** 2023-01-30
- **Final completion:** 2024-05-07
- **Target enrollment:** 331 (ACTUAL)
- **Last updated:** 2025-05-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05149313

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05149313, "A Study of Lebrikizumab in Combination With Topical Corticosteroids in Patients With Atopic Dermatitis (AD) That Are Not Adequately Controlled With or Are Non-eligible for Cyclosporine". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05149313. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*